Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

数十年来肺癌罹患机率整体下降，但不曾抽烟的亚裔美国人得肺癌机率却越来越高; 示意图。（图/123RF） 雅虎生活新闻（Yahoo Life）27日报导，专门研究亚裔美国人未抽烟却得肺癌趋势的斯坦福大学（Stanford ...

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...

Hutchmed (HCM) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA, has granted breakthrough therapy designation, or BTD, to the combination of ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...